Deka Biosciences Inc.'s IND application has been cleared by the FDA allowing the company to proceed with a phase I trial of DK-210 (EGFR) in patients with advanced solid cancer overexpressing epidermal growth factor receptors (EGFR).

Breast cancer-associated gene 1 (BRCA1) is a critical tumor suppressor in breast cancer, and BRCA1 deficiency impairs DNA damage repair, leading to DNA damage accumulation and subsequent genetic alterations that result in the onset of breast cancer. In the current study, researchers from the University of Macau aimed to identify the potential factors that may participate in BRCA1-associated tumorigenesis.

Help Therapeutics Co. Ltd. has received IND approval from China's Center for Drug Evaluation (CDE) for HiCM-188.

Intrahepatic cholangiocarcinoma (ICC) is a disease characterized by rapid progression, high relapse rate and high mortality.

Zedira GmbH has synthesized protein-glutamine γ-glutamyltransferase (TGM2) inhibitors reported to be useful for the treatment of celiac disease.